---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-081797"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-07-08T20:23:21+00:00"
generated_at: "2026-07-08T20:24:06.032931+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Oncolytics Biotech disengages EY, engages Baker Tilly as auditor after restructuring

## Summary
- Audit committee voted to disengage EY and engage Baker Tilly for fiscal 2026, subject to client acceptance.
- EY's reports for 2024 and 2025 contained no adverse opinion but included a going-concern explanatory paragraph.
- No disagreements or reportable events with EY during the fiscal years ended 2024 and 2025.
- Company provided EY with a copy of the 8-K and requested a letter to the SEC regarding the statements.

## SEC filing metadata
- accession: 0001104659-26-081797
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-07-08T20:23:21+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000110465926081797/0001104659-26-081797-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000110465926081797/tm2620055d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-081797
- JSON: https://secwatch.observer/filing/0001104659-26-081797.json
- Plain text: https://secwatch.observer/filing/0001104659-26-081797.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.